1 week Ago By Defense World Staff
Bank of Montreal Can cut its stake in shares of Acelyrin, Inc. (NASDAQ:SLRN – Free Report) by 90.2% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC).
The fund owned 14,532 shares of the company’s stock after selling 134,103 shares during the quarter. Bank of Montreal Can’s holdings in Acelyrin were worth $46,000 as of its most recent filing with the Securities and Exchange Commission (SEC). A number of other hedge funds and other institutional investors have also bought and sold shares of SLRN.
Geode Capital Management LLC grew its position in Acelyrin by 30.8% during the third quarter. Geode Capital Management LLC now owns 1,651,614 shares of the company’s stock valued at $8,144,000 after acquiring an additional 388,631 shares during the last quarter.
Wellington Management Group LLP purchased a new position in shares of Acelyrin during the fourth quarter valued at approximately $567,000. ExodusPoint Capital Management LP bought a new position in Acelyrin in the 4th quarter worth $423,000. State Street Corp boosted its stake in shares of Acelyrin by 10.
0% during the 3rd quarter. State Street Corp now owns 1,273,096 shares of the company’s stock valued at $6,276,000 after purchasing an additional 116,094 shares in the last quarter. Finally, Barclays PLC increased its position in shares of Acelyrin by 208.
8% during the third quarter. Barclays PLC now owns 96,408 shares of the company’s stock valued at $475,000 after buying an additional 65,188 shares during the period. Hedge funds and other institutional investors own 87.
31% of the company’s stock. Insider Transactions at AcelyrinIn other news, CEO Mina Kim sold 17,986 shares of the company’s stock in a transaction on Monday, March 17th. The stock was sold at an average price of $2.
74, for a total transaction of $49,281.64. Following the transaction, the chief executive officer now directly owns 671,753 shares of the company’s stock, valued at $1,840,603.
22. This represents a 2.61 % decrease in their ownership of the stock.
The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Insiders own 13.60% of the company’s stock.
Acelyrin Stock PerformanceShares of SLRN opened at $2.17 on Friday. Acelyrin, Inc.
has a fifty-two week low of $1.85 and a fifty-two week high of $7.25.
The firm’s 50-day simple moving average is $2.47 and its two-hundred day simple moving average is $3.36.
The stock has a market cap of $218.97 million, a PE ratio of -0.88 and a beta of 1.
12. Acelyrin (NASDAQ:SLRN – Get Free Report) last posted its quarterly earnings results on Wednesday, March 19th. The company reported ($0.
79) earnings per share for the quarter, topping the consensus estimate of ($0.86) by $0.07.
Equities research analysts predict that Acelyrin, Inc. will post -2.53 EPS for the current year.
Analyst Upgrades and DowngradesSLRN has been the subject of several research analyst reports. Citigroup lowered their price objective on shares of Acelyrin from $6.00 to $3.
00 and set a “neutral” rating for the company in a report on Tuesday, January 7th. HC Wainwright dropped their price target on Acelyrin from $8.00 to $6.
00 and set a “neutral” rating on the stock in a research report on Tuesday, January 7th. Three research analysts have rated the stock with a hold rating and two have assigned a buy rating to the company. According to data from MarketBeat, Acelyrin currently has an average rating of “Hold” and a consensus price target of $9.
60.View Our Latest Research Report on AcelyrinAcelyrin Profile (Free Report)Acelyrin, Inc, a clinical biopharma company, focuses on identifying, acquiring, and accelerating the development and commercialization of transformative medicines. The company's lead product candidate is izokibep, a small protein therapeutic designed to inhibit IL-17A with high potency, which is in Phase 3 clinical trials for use in the treatment of Hidradenitis Suppurativa, Psoriatic Arthritis, and uveitis, as well as in Phase 2 clinical trials for use in the treatment of Axial Spondyloarthritis.
Featured ArticlesFive stocks we like better than AcelyrinWhat Is WallStreetBets and What Stocks Are They Targeting?Markets Think Robinhood Earnings Could Send the Stock UpTransportation Stocks InvestingChurchill Downs Stock: Could Tariff Fears Dampen Derby Gains?3 Small Caps With Big Return PotentialAT&T: Subscriber Growth & Buybacks Signal Bullish Turnaround.
